The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.
about
Oncolytic virotherapy using herpes simplex virus: how far have we come?Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapyOncolytic virus therapy for glioblastoma multiforme: concepts and candidatesVirotherapy: cancer gene therapy at last?Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.Human gene therapy and imaging in neurological diseases.Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulationA phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.Herpes simplex virus oncolytic therapy for pediatric malignanciesEvaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells.Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersTargeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.Herpesvirus vectors for therapy of brain tumors.Experimental approaches for the treatment of malignant gliomas.An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma.Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptorTargeting cancer-initiating cells with oncolytic viruses.Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.Clinical development of experimental therapies for malignant glioma.Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProduction of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1Gene therapy and targeted toxins for glioma.Gene therapy for pain: results of a phase I clinical trial.Neurovirological methods and their applications.Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cellsUnlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacyGene therapy for malignant glioma.ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.Oncolytic viral therapies.Gene therapy trials for the treatment of high-grade gliomas.Attenuated herpes simplex virus 1 blocks arterial apoptosis and intimal hyperplasia induced by balloon angioplasty and reduced blood flow.Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12
P2860
Q26862461-51E7FF12-2474-4BA6-B342-A6FBABBBBCBFQ26998111-5D176A02-4026-456C-8D1D-0044E2C9531EQ27007519-A1C0F619-E3FA-468E-A911-4DD2DAD29492Q28066228-202D5DA0-33EE-4B9E-A4BA-04470C2E864AQ30395978-71D11BAE-67DE-4CD4-A919-165F72163138Q30954768-0CEF0AA5-B23B-4F04-AF6B-5DCE627A237EQ31023442-F7F45441-1A37-42F1-917D-9F4D4B536FFFQ33566511-6244CDF8-DEB9-40FA-86D7-35E96BE3578AQ33587028-E4B6EE7D-B367-434D-A4BA-C849228C6F0BQ33713824-966ED8C2-88D2-4094-BE5D-B4A21E509F72Q33720628-75F279B9-6C42-4268-94C7-8E9832212646Q33755158-AD146827-4D6C-42F4-A27B-3E7AEDD86DC9Q33923950-7625710A-B1B7-4C77-B765-27C3CEEECD2AQ33985663-7F1E9DF0-6276-40D4-A84E-6A06C8EE7ECCQ34073330-B34B74CC-08BC-4E0C-A51F-3E275719DC4DQ34091990-FBE980BA-8325-4955-ADA2-1ED93A238C3CQ34127138-DD174F88-E9A6-475A-ACF9-9320DE41C077Q34220547-174BEEF6-14BD-423D-85D2-32370D155EF4Q34275711-9A9A94E5-1B37-4805-AC55-8BE7E7E5A92AQ34343768-EC4D76CC-B503-4B1C-A220-DD1C616CE018Q34506962-D21F576C-2BD6-4F1D-A9E5-4EEA0776A47EQ34600345-E3BFC457-2651-4C55-BB82-DCEF764CEE9BQ34659011-E5204393-BAF9-4188-A8D4-0E038BCCFB76Q34673668-FFBE6DB7-0900-4495-B037-435E7F5E2533Q34770256-30272AF9-29FC-4587-A3E2-FFBBAFF608FDQ34782295-F331EF49-1C0D-43CD-8274-D16B5018F20FQ35036505-8F197E3B-F5BE-4E4B-8FD9-77536CA8DBDAQ35060701-67A9792D-5044-4006-AD37-855361102B67Q35118933-B3F73C91-81E9-41E8-AC75-D6D09CD57DFCQ35154100-B159262E-C908-42F9-A34D-D7CD350634B6Q35183104-5D0C5919-0927-454E-84B5-C1AE69DF7219Q35216380-7FEB71CF-222E-4A9C-8E49-42595AA34B25Q35545752-A249BF18-848B-42F6-9F10-A1CE30D662E5Q35657822-FAD72D21-9BE8-4A21-8C3D-1425DC923C37Q35673628-DF4364FD-666F-4CBD-87D8-1B186A0D3D0BQ35699072-95C34B79-F26D-4C8F-A4E5-3D81C5FBEFFFQ35852258-A1050031-4F5A-4EE7-B917-A7A7CE59CB01Q35880459-A8CA1E60-C119-4D07-B457-0C90EB10255FQ35927978-5E48E7DF-5251-4CF9-A3A0-BC816EB228E6Q35943736-F4771550-AB2B-40A2-B347-7AE6AFA1ABEF
P2860
The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The potential for efficacy of ...... a: a proof of principle study.
@ast
The potential for efficacy of ...... a: a proof of principle study.
@en
The potential for efficacy of the modified
@nl
type
label
The potential for efficacy of ...... a: a proof of principle study.
@ast
The potential for efficacy of ...... a: a proof of principle study.
@en
The potential for efficacy of the modified
@nl
prefLabel
The potential for efficacy of ...... a: a proof of principle study.
@ast
The potential for efficacy of ...... a: a proof of principle study.
@en
The potential for efficacy of the modified
@nl
P2093
P2860
P356
P1433
P1476
The potential for efficacy of ...... a: a proof of principle study.
@en
P2093
Papanastassiou V
Rampling R
P2860
P2888
P304
P356
10.1038/SJ.GT.3301664
P577
2002-03-01T00:00:00Z